Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -12.16%35.39M | -18.17%35.19M | -8.28%38.12M | 5.23%167.57M | 4.50%42.72M | -6.07%40.29M | 11.07%43M | 13.09%41.56M | -2.44%159.24M | 8.80%40.88M |
| Operating revenue | -12.16%35.39M | -18.17%35.19M | -8.28%38.12M | 5.23%167.57M | 4.50%42.72M | -6.07%40.29M | 11.07%43M | 13.09%41.56M | -2.44%159.24M | 8.80%40.88M |
| Cost of revenue | -10.79%19.81M | -14.68%19.03M | -21.02%19.24M | -3.76%92.45M | -5.53%23.58M | -24.85%22.2M | 9.76%22.31M | 14.70%24.36M | 8.21%96.07M | 16.20%24.96M |
| Gross profit | -13.84%15.58M | -21.93%16.15M | 9.75%18.88M | 18.91%75.11M | 20.23%19.14M | 35.48%18.08M | 12.51%20.69M | 10.89%17.2M | -15.13%63.17M | -1.07%15.92M |
| Operating expense | -10.11%19.12M | -3.32%19.85M | -2.55%21.04M | -7.93%84.61M | -3.61%21.22M | -2.54%21.27M | -13.98%20.53M | -11.24%21.59M | -34.46%91.9M | -10.29%22.01M |
| Selling and administrative expenses | -4.42%14.48M | 6.44%15.25M | 7.29%16.33M | -7.50%59.87M | -0.44%15.17M | -0.49%15.15M | -16.00%14.33M | -12.19%15.22M | -40.08%64.73M | -11.04%15.24M |
| -Selling and marketing expense | 12.40%1.01M | 39.30%1.24M | 28.08%1.15M | -17.41%3.59M | -0.54%913K | -13.86%895K | -26.00%888K | -24.87%894K | -9.40%4.35M | -20.93%918K |
| -General and administrative expense | -5.48%13.47M | 4.27%14.01M | 6.00%15.18M | -6.79%56.28M | -0.43%14.26M | 0.49%14.25M | -15.25%13.44M | -11.26%14.33M | -41.51%60.38M | -10.32%14.32M |
| Depreciation amortization depletion | -24.18%4.64M | -25.85%4.6M | -26.08%4.71M | -8.96%24.74M | -10.73%6.05M | -7.28%6.12M | -8.90%6.2M | -8.88%6.37M | -13.44%27.17M | 2.59%6.77M |
| -Depreciation and amortization | -24.18%4.64M | -25.85%4.6M | -26.08%4.71M | -8.96%24.74M | -10.73%6.05M | -7.28%6.12M | -8.90%6.2M | -8.88%6.37M | -13.44%27.17M | 2.59%6.77M |
| Provision for doubtful accounts | ---- | ---- | ---- | 289.77%1.18M | ---- | ---- | ---- | ---- | 359.09%303K | ---- |
| Operating profit | -11.10%-3.53M | -2,441.14%-3.7M | 50.77%-2.16M | 66.96%-9.49M | 65.87%-2.08M | 62.45%-3.18M | 102.88%158K | 50.20%-4.39M | 56.33%-28.73M | 27.85%-6.09M |
| Net non-operating interest income (expenses) | -2.24%-4.83M | -250.97%-9.21M | 344.38%11.17M | 9.37%-16.64M | 2.52%-4.72M | -9.92%-4.72M | 42.65%-2.63M | 2.99%-4.57M | -43.29%-18.36M | 34.07%-4.84M |
| Non-operating interest income | -32.19%554K | ---- | 2,442.02%16.57M | 286.51%5.16M | 252.53%906K | 14.75%817K | 839.53%2.78M | --652K | -90.34%1.33M | -66.45%257K |
| Non-operating interest expense | -2.83%5.38M | 70.42%9.21M | 3.39%5.4M | 10.67%21.8M | 10.33%5.63M | 10.60%5.54M | 10.94%5.41M | 10.84%5.22M | -26.01%19.7M | -42.79%5.1M |
| Other net income (expenses) | -137.30%-711K | -319.80%-1.68M | 121.26%145K | 134.56%819K | 98.70%-7K | 190,700.00%1.91M | -10.83%-399K | 46.38%-682K | 99.34%-2.37M | 98.31%-539K |
| Gain on sale of security | ---- | 75.00%-4K | -157.14%-4K | 37.84%-46K | 79.78%-18K | -132.76%-19K | -45.45%-16K | 121.21%7K | 82.46%-74K | -85.42%-89K |
| Special income (charges) | -136.94%-711K | -336.29%-1.67M | 121.63%149K | 137.67%865K | 102.44%11K | 3,362.71%1.93M | -9.74%-383K | 61.81%-689K | 99.36%-2.3M | 98.58%-450K |
| -Less:Restructuring and mergern&acquisition | --25K | -46.75%41K | --0 | -76.85%257K | -99.41%3K | --0 | -77.68%77K | --178K | -91.72%1.11M | -56.22%507K |
| -Less:Impairment of capital assets | ---- | ---- | --0 | -1,855.64%-2.6M | -201.19%-253K | ---- | ---- | -126.31%-136K | -100.44%-133K | ---84K |
| -Less:Other special charges | ---- | ---- | ---- | -91.15%114K | --0 | ---- | ---- | -91.15%114K | -99.59%1.29M | --0 |
| -Less:Write off | 135.64%686K | 432.68%1.63M | -127.95%-149K | 4,303.23%1.37M | 785.19%239K | -2,689.86%-1.93M | 7,550.00%306K | 53,400.00%533K | 110.76%31K | -95.78%27K |
| Other non-operating income (expenses) | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 15.40%652K | ---- | ---- |
| Income before tax | -51.29%-9.07M | -408.97%-14.59M | 194.99%9.16M | 48.82%-25.31M | 40.68%-6.81M | 53.03%-6M | 72.48%-2.87M | 34.83%-9.64M | 88.73%-49.46M | 75.90%-11.48M |
| Income tax | -38.49%3.47M | -40.33%4.13M | -7.97%4.01M | -165.08%-17.68M | -579.45%-34.6M | -11.98%5.65M | -28.88%6.92M | 14.66%4.36M | 154.07%27.16M | 285.05%7.22M |
| Earnings from equity interest net of tax | ||||||||||
| Net income | -7.76%-12.55M | -91.21%-18.72M | 136.79%5.15M | 90.03%-7.64M | 248.67%27.79M | 39.31%-11.64M | 51.42%-9.79M | 24.72%-14M | 82.95%-76.62M | 57.25%-18.7M |
| Net income continuous operations | -7.76%-12.55M | -91.21%-18.72M | 136.79%5.15M | 90.03%-7.64M | 248.67%27.79M | 39.31%-11.64M | 51.42%-9.79M | 24.72%-14M | 82.95%-76.62M | 57.25%-18.7M |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | -7.76%-12.55M | -91.21%-18.72M | 136.79%5.15M | 90.03%-7.64M | 248.67%27.79M | 39.31%-11.64M | 51.42%-9.79M | 24.72%-14M | 82.95%-76.62M | 57.25%-18.7M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | -7.76%-12.55M | -91.21%-18.72M | 136.79%5.15M | 90.03%-7.64M | 248.67%27.79M | 39.31%-11.64M | 51.42%-9.79M | 24.72%-14M | 82.95%-76.62M | 57.25%-18.7M |
| Diluted earnings per share | 0 | 0 | 0 | 0 | 0.01 | 0 | 0 | 0 | 92.31%-0.01 | 0 |
| Basic earnings per share | 0 | 0 | 0 | 0 | 0.01 | 0 | 0 | 0 | 92.31%-0.01 | 0 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.